1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Kuhnil Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016

Kuhnil Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016

  • June 2016
  • -
  • Global Markets Direct
  • -
  • 39 pages

Kuhnil Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Kuhnil Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016’, provides an overview of the Kuhnil Pharmaceutical Co., Ltd.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Kuhnil Pharmaceutical Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Kuhnil Pharmaceutical Co., Ltd.
- The report provides overview of Kuhnil Pharmaceutical Co., Ltd. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Kuhnil Pharmaceutical Co., Ltd.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Kuhnil Pharmaceutical Co., Ltd.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Kuhnil Pharmaceutical Co., Ltd.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Kuhnil Pharmaceutical Co., Ltd.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Kuhnil Pharmaceutical Co., Ltd.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table Of Contents

Kuhnil Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016
Table of Contents
Table of Contents 2

Kuhnil Pharmaceutical Co., Ltd. Snapshot 5
Kuhnil Pharmaceutical Co., Ltd. Overview 5
Key Information 5
Key Facts 5
Kuhnil Pharmaceutical Co., Ltd. - Research and Development Overview 6
Key Therapeutic Areas 6
Kuhnil Pharmaceutical Co., Ltd. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Partnered Products 10
Partnered Products/Combination Treatment Modalities 11
Kuhnil Pharmaceutical Co., Ltd. - Pipeline Products Glance 12
Kuhnil Pharmaceutical Co., Ltd. - Late Stage Pipeline Products 12
Phase III Products/Combination Treatment Modalities 12
Kuhnil Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
Kuhnil Pharmaceutical Co., Ltd. - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
Kuhnil Pharmaceutical Co., Ltd. - Drug Profiles 17
KI-0501 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
nimotuzumab 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
KI-0503 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
KI-1102 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
KI-1104 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
KI-0801 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
KI-1002 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
KI-1003 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
KI-1007 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
KI-1101 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
KI-1103 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
KI-1105 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
Kuhnil Pharmaceutical Co., Ltd. - Pipeline Analysis 32
Kuhnil Pharmaceutical Co., Ltd. - Pipeline Products by Target 32
Kuhnil Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration 33
Kuhnil Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type 34
Kuhnil Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action 35
Kuhnil Pharmaceutical Co., Ltd. - Recent Pipeline Updates 36
Kuhnil Pharmaceutical Co., Ltd. - Locations And Subsidiaries 37
Head Office 37
Other Locations and Subsidiaries 37
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 38
Disclaimer 39

List of Tables
Kuhnil Pharmaceutical Co., Ltd., Key Information 5
Kuhnil Pharmaceutical Co., Ltd., Key Facts 5
Kuhnil Pharmaceutical Co., Ltd. - Pipeline by Indication, 2016 7
Kuhnil Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2016 8
Kuhnil Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2016 9
Kuhnil Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2016 10
Kuhnil Pharmaceutical Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2016 11
Kuhnil Pharmaceutical Co., Ltd. - Phase III, 2016 12
Kuhnil Pharmaceutical Co., Ltd. - Phase II, 2016 13
Kuhnil Pharmaceutical Co., Ltd. - Phase I, 2016 14
Kuhnil Pharmaceutical Co., Ltd. - Preclinical, 2016 15
Kuhnil Pharmaceutical Co., Ltd. - Discovery, 2016 16
Kuhnil Pharmaceutical Co., Ltd. - Pipeline by Target, 2016 32
Kuhnil Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2016 33
Kuhnil Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2016 34
Kuhnil Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2016 35
Kuhnil Pharmaceutical Co., Ltd. - Recent Pipeline Updates, 2016 36
Kuhnil Pharmaceutical Co., Ltd., Other Locations 37

List of Figures
Kuhnil Pharmaceutical Co., Ltd. - Pipeline by Top 10 Indication, 2016 7
Kuhnil Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2016 8
Kuhnil Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2016 9
Kuhnil Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2016 10
Kuhnil Pharmaceutical Co., Ltd. - Pipeline by Target, 2016 32
Kuhnil Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2016 33
Kuhnil Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2016 34
Kuhnil Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2016 35

Companies Mentioned

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.